AGM Presentation
Filed with ASX · · 22 pages · English
Summary by 6ix AI
Acrux Limited has released its AGM presentation detailing the addresses from its Chairman and CEO at the company's annual general meeting. The presentation outlines the company's achievements over the past year, including product launches and regulatory submissions. Acrux is focused on developing and commercializing topical pharmaceutical products, primarily in the United States market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- FY24 R&D Tax Incentive rebate received
- ASX Small and Mid Cap Conference presentation
- FY24 Full Year Results - Investor Presentation
- Appendix 4E and FY24 Full Year Statutory Accounts
- FDA Approval received for Dapsone Gel, 7.5%
Later from Acrux
- Trading Halt
- FDA Approval - Nitroglycerin Ointment
- Share Placement successfully concluded and SPP launched
- Investor Presentation
- Share Purchase Plan Offer Booklet
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux